Nanobiotix S.A.
NBTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001760854
No open-market purchases or sales by Nanobiotix S.A. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $218.4M in total; no superinvestor holds it.
Other share classesNNBXF
13F holders, Q1 2025
Institutional positions in Nanobiotix S.A. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −6 vs. Q4 2024
- Shares held
- 5.76M
- −306.0K (−5.0%) vs. Q4 2024
- Total value
- $20.6M
- +$3.21M (+18.4%) vs. Q4 2024
- New holders
- 1
- 2 more added
- Sold out
- 7
- 4 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $218.4M |
| Q1 2026 | 15 | $175.9M |
| Q4 2025 | 14 | $131.8M |
| Q3 2025 | 11 | $106.6M |
| Q2 2025 | 10 | $25.6M |
| Q1 2025 | 12 | $20.6M |
| Q4 2024 | 18 | $17.4M |
| Q3 2024 | 10 | $36.9M |
| Q2 2024 | 12 | $46.5M |
| Q1 2024 | 12 | $59.7M |
| Q4 2023 | 12 | $67.5M |
| Q3 2023 | 9 | $39.1M |
| Q2 2023 | 5 | $17.7M |
| Q1 2023 | 4 | $12.4M |
| Q4 2022 | 5 | $12.2M |
| Q3 2022 | 5 | $12.2M |
| Q2 2022 | 6 | $13.3M |
| Q1 2022 | 6 | $26.0M |
| Q4 2021 | 7 | $28.8M |
| Q3 2021 | 9 | $46.5M |
| Q2 2021 | 10 | $66.9M |
| Q1 2021 | 10 | $73.2M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Nanobiotix S.A.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Johnson & Johnson | 5,623,816 | $20.1M | 5.89% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 105,053 | $376.1K | 0.01% | −161,040−60.5% | Reduced |
| Jane Street Group, LLC | 11,387 | $40.8K | 0.00% | −11,896−51.1% | Reduced |
| Geode Capital Management, LLC | 10,184 | $36.1K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 6,100 | $21.8K | 0.00% | +998+19.6% | Added |
| UBS Group AG | 3,000 | $10.7K | 0.00% | −817−21.4% | Reduced |
| Bank of America Corp | 706 | $2.53K | 0.00% | −1,711−70.8% | Reduced |
| BNP Paribas Arbitrage, SA | 661 | $2.34K | 0.00% | +661 | New |
| Citigroup Inc | 241 | $853 | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 33 | $116 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 4 | $14 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 136 | $0 | 0.00% | +7+5.4% | Added |
| BlackRock, Inc. | 0 | $0 | 0.00% | −51,484−100.0% | Sold out |
| Old Mission Capital LLC | 0 | $0 | 0.00% | −48,474−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −13,452−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,498−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −7,921−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −256−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −154−100.0% | Sold out |